Patent Application
20070117982
The present invention relates to the production of 2-unsaturated azasteroids and the use thereof for producing medicaments.
Azasteroids are compounds with a high potential for pharmacological effect. Various representatives of this class of compound have been approved as medicaments for a relatively long period (finasteride) or recently (turosteride). A series of methods of producing the pharmaceutically employed azasteroids, primarily for the active ingredient finasteride, has become known. Their synthesis starts from commercially available steroid intermediates (e.g. pregnenolone acetate, androstenolone acetate), which for their part are usually obtained from vegetable sources.
Of particular importance is the insertion of a double bond in ring A of the steroid basic structure between carbons 1 and 2 since, by doing so, for example in the case of the medicament finasteride, it was possible to achieve an increase in effectiveness and a reduction in the single dose. A series of direct and indirect (indirectly via electrophilic addition/substitution with subsequent elimination) oxidation methods have become known and are the subject matter of numerous patent specifications. However, only small yields are often quoted for these methods, or toxic reagents, such as phenylselenic anhydride or diphenyl diselenide, are used.
As regards azasteroids with antiandrogenic properties, the insertion of the 1,2 double bond into the compound 4-methyldihydrofinasteride (general formula II: R1=NR2′R3′, where R2′ is H and R3′ is tert-butyl, R2=methyl, in which - - - marks single bonds and the A and B ring of the steroid are trans linked) through indirect oxidation has become known, where firstly the starting material is deprotonated with the base lithium diisopropylamide, than a thiophenyl group is inserted by means of diphenyl disulfide. Following purification by column chromatography, the thioether group is oxidized by means of sodium metaperiodate and the resulting intermediate is heated for the elimination in toluene. The end product was obtained following purification by column chromatography. The insertion of the 1,2 double bond into an azasteroid by the disulfide method is also described by reference to the synthesis of the 3-O-lactim ether of dihydrofinasteride. This 3-O-methyl group can be regarded as protective group (for avoiding the use of a further excess of lithium diisopropylamide for deprotonation of the proton on the nitrogen in position 4). After dehydrogenation, finasteride can be obtained through cleavage of the lactime ether. The method proceeds in a complicated manner and in poor yields. Considering the difficult handling and the price of organolithiums, the poor yields and the complexity of work-up and purification by column chromatography, it is no wonder that the disulfide method has not subsequently been pursued further and there has resulted instead the mentioned diversity of synthesis patents.
In the course of our own investigations, the inefficiency of using lithium diisopropylamide/diphenyl disulfide and the published synthesis procedures for inserting the 1,2 double bond into azasteroids was confirmed.
The basis of the present invention lies in the use of alkali metal alkoxides in inert solvents, which has proven not only to be optimal for the targeted deprotonation of azasteroids in the alpha position relative to the carbonyl group, but also, in contrast to the previously published methods, allows the 1,2-dehydrogenation to proceed in very good to excellent yields. The use of alkoxides dispenses with the use of difficult-to-handle and expensive organolithiums. The high yield during the production of the intermediate also permits its isolation and pure production and makes that of the end product significantly easier, without complex separation procedures. To achieve the required pharmaceutical grade, impurities must be able to be separated off from medicaments in the one tenth percent range. Since the dihydroazasterols themselves are a critical impurity of the azasterols, the high conversion rates during the reaction possible through the invention are of particular importance.
The present invention thus provides a method of producing 1,2-unsaturated azasteroids of the general formula I,
in which
According to one feature of the invention, the alkali metal salt of a lower branched or unbranched alcohol used in step (a) may be a sodium or potassium alkoxide. Preferred alkali metal alkoxides are sodium methoxide, sodium ethoxide and potassium tert-butoxide. One of the advantages of this invention is that the alkoxides to be used are not expensive and are easier to handle.
According to one feature of the invention, the inert solvent used in step (a) is a non-pure alcoholic solvent, for example an ether. A preferred solvent is tetrahydrofuran.
According to one feature of the invention, the aryl disulfide of the general formula III in step (a) can be added to the reaction mixture at the start. The aryl disulfide used can, for example, be diphenyl disulfide.
It is an advantage of the invention that the insertion of the thioether group in step (a) of the method according to the invention takes place in good to excellent yield.
According to one feature of the invention, the thioether intermediate in step (b) can be separated off from the remains of the starting material of the general formula II and from excess reagent of the formula III or from aromatic thiol by means of start-point filtration over silica gel.
In step (c) of the method according to the invention, the sulfur of the thioether intermediate is oxidized with a reagent suitable for the oxidation of thioethers. According to one feature of the invention, the oxidation can be carried out with an alkali metal metaperiodate or an alkali metal permanganate.
The 1,2 double bond can then be introduced according to the invention through simple heating in an inert solvent. The inert solvent used in step (d) can be a substituted or unsubstituted inert aromatic solvent. A preferred solvent is xylene.
According to one feature of the invention, isolation with the end product in step (e) can take place upon cooling though crystallization in crystalline, largely pure form, from the reaction mixture.
A preferred solvent for use in step (d) of the method according to the invention is xylene. On account of the high boiling point of xylene, the reaction is rapid, and on account of the poorer solubility of azasteroids in xylene compared with toluene, spontaneous crystallization starts more easily upon cooling. As a result, work-up of the reaction mixture, particularly on the industrial scale, is greatly simplified. Finally, the end product is obtained preferably by crystallization in crystalline, largely pure form from the reaction mixture.
The resulting end product can, if necessary, be recrystallized in a further step in order to remove residual amounts of slight impurities. Solvents suitable for the recrystallization are, for example, those chosen from the group consisting of xylene, dioxane, isopropanol or a mixture of these solvents.
According to one feature of the invention, the starting material used is dihydrofinasteride (general formula II: R1 =NR2′R3′, where R2′ is H and R3′ is tert-butyl, R2 =H, in which - - - marks single bonds and the A and B ring of the steroid are trans linked), which reacts to give the product finasteride (general formula I: R1 =NR2′R3′, where R2′ is H and R3′ is tert-butyl, R2 =H and - - - marks single bonds and the A and B ring of the steroid are trans linked).
According to one feature of the invention, the alkoxides in step (a) can be used in a defined molecular ratio to the starting material, where at least one 1 mol equivalent and at most 3 mol equivalents, but preferably 2 mol equivalents, of alkoxide are used.
According to one feature of the invention, the reaction can be carried out in an ethereal solvent, preferably tetrahydrofuran, and proceed at elevated temperature, preferably the boiling temperature of the solvent.
According to one feature of the invention, turosteride is produced by the method according to the invention.
According to one feature of the invention, the 1,2-unsaturated azasteroids produced by the method according to the invention are used for producing medicaments.
Specific embodiments of the invention are illustrated below by reference to nonlimiting examples.
10 g of dihydrofinasteride are suspended in 100 ml of anhydrous tetrahydrofuran under an argon atmosphere (exclusion of moisture) and heated with 2.87 g of Na methoxide and 28.75 g of diphenyl disulfide at boiling for 16 h. The reaction is then cooled, the mixture is diluted with dichloroethane and 2N sulfuric acid, the phases are separated and extracted by shaking with in each case 2N sulfuric acid, 2N sodium hydroxide solution, and water, and evaporation is carried out. This gives 36.138 g of a yellowish mass which crystallizes from the melt.
1.5 g of dihydrofinasteride are suspended in 15 ml of anhydrous tetrahydrofuran under an argon atmosphere (exclusion of moisture) and heated with 0.544 g of Na ethoxide and 4.31 g of diphenyl disulfide at boiling for 16 h.
The reaction is then cooled, the mixture is diluted with 15 ml of dichloroethane and 15 ml of 2N sulfuric acid, the phases are separated and extracted by shaking with in each case 15 ml of 2N sulfuric acid, 2N sodium hydroxide solution, and water, and evaporation is carried out. This gives 1.80 g of a yellowish mass which crystallizes from the melt.
1.5 g of dihydrofinasteride are suspended in 15 ml of anhydrous tetrahydrofuran under an argon atmosphere (exclusion of moisture) and heated with 0.90 g of K tert-butoxide and 4.31 g (20.0 mmol) of diphenyl disulfide at boiling for 16 h.
The reaction is then cooled, the mixture is diluted with 15 ml of dichloroethane and 15 ml of 2N sulfuric acid, the phases are separated and extracted by shaking with in each case 15 ml of 2N sulfuric acid, 2N sodium hydroxide solution, and water, and evaporation is carried out. This gives 1.76 g of a yellowish mass which crystallizes from the melt.
36 g of crude mass of the thioether intermediate (Examples 1 to 3) are dissolved in 100 ml of dichloromethane, and subjected to start-point filtration over a bed of 200 g of silica gel with petroleum ether:methyl tert-butyl ether =20:1. After the elution, 12.3 g of the largely pure thioether intermediate is obtained.
12.27 g of thioether intermediate are taken off in 130 ml of methanol with 20% water content and stirred with 13.5 g of sodium metaperiodate at room temperature for 16 h.
Then, the mixture is diluted with dichloroethane and water, the phases are separated and extracted again by shaking with dichloroethane. Following evaporation, 14.2 g of a delicate-yellow solid are obtained.
This solid is taken up in xylene and heated at reflux for 2 h. Upon cooling with stirring, crystallization starts. The crystals are filtered off with suction and then washed with xylene. This gives 8.4 g of finasteride.
8 g of finasteride from Example 5 are dissolved in isopropanol with heating, inoculated upon cooling and left for 16 hours at 5° C. The crystals are filtered off with suction and dried under reduced pressure. This gives 5.6 g of finasteride.
| Number | Date | Country | Kind |
|---|---|---|---|
| 4/2004 | Jan 2004 | AT | national |
